Bookbot

Modern Strategy for Preclinical Pharmaceutical R&D

Towards the Virtual Research Company

Meer over het boek

The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.

Een boek kopen

Modern Strategy for Preclinical Pharmaceutical R&D, David Cavalla, John Flack, Richard Jennings

Taal
Jaar van publicatie
1997
product-detail.submit-box.info.binding
(Hardcover)
Zodra we het ontdekt hebben, sturen we een e-mail.

Betaalmethoden

Nog niemand heeft beoordeeld.Tarief

Titel
Modern Strategy for Preclinical Pharmaceutical R&D
Ondertitel
Towards the Virtual Research Company
Taal
Engels
Uitgever
Wiley
Jaar van publicatie
1997
Formaat
Hardcover
Aantal pagina's
228
ISBN10
0471971170
ISBN13
9780471971177
Reeks
Aantekening
The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.